Oncimmune Hldngs PLC

Notice of AGM and Posting of Annual Report

RNS Number : 5895E
Oncimmune Holdings PLC
09 November 2020

9 November 2020



Oncimmune Holdings plc


("Oncimmune" or the "Company")


Notice of Annual General Meeting and Posting of Annual Report


Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, today gives notice that its Annual General Meeting ("AGM") will be held at 10:00 am on 30 November 2020 at the offices of Zeus Capital, 10 Old Burlington Street, London, W1S 3AG .


The Company's Annual Report and Accounts for the year ended 31 May 2020 and the Notice of Annual General Meeting have been sent to shareholders and can also be viewed on the "Investors" section of the Company's website at www.oncimmune.com .


As a result of the current UK Government guidance on social distancing and prohibiting public gathering over certain numbers, the Company has taken the decision that this year unfortunately it will not be possible for shareholders to attend the AGM in person. The AGM will therefore be primarily functional in formation with only a small number of Directors and/or other employee shareholders attending in person.


Details on how shareholders can vote by proxy are set out in the Notice of Annual General Meeting. The Company therefore requests that shareholders appoint the Chairman of the meeting as a proxy and provide their voting responses in advance of the AGM.


In order to facilitate engagement with shareholders, shareholders can submit questions to the Directors ahead of the AGM by email to [email protected] . The Directors will endeavour to respond to appropriately raised questions in a timely manner.



For further information:


Oncimmune Holdings plc

Adam Hill, Chief Executive Officer

Matthew Hall, Chief Financial Officer

[email protected]


Zeus Capital Limited (Nominated Adviser and Joint Broker)

Andrew Jones, Daniel Harris, Victoria Ayton

+44 (0)20 3829 5000


N+1 Singer (Joint Broker)

Aubrey Powell, Harry Gooden, Iqra Amin, James Fischer

+44 (0)20 7496 3000


WG Partners (Joint Broker)

David Wilson, Chris Lee

+44 (0)20 3705 9321


Media enquiries:

FTI Consulting

Ben Atwell, Michael Trace, Alex Davis

[email protected]

+44 (0)20 3727 1000


About Oncimmune


Our intimate understanding of the human immune system enables us to harness its sophisticated response to disease to detect cancer earlier and to support the development of better therapies. The key to improving cancer survival is early detection and better selection for therapy. As a company, we are driven by our passion to improve cancer survival and to give people extra time.


Oncimmune is a leading immunodiagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. Oncimmune has a diversified and growing revenue from its portfolio of diagnostic products to detect early-stage cancer and a contract discovery and development service-based platform, delivering actionable insights into therapies to its pharmaceutical and biotech partners .


Oncimmune's ImmunoINSIGHTS platform enables life-science organisations to optimise drug development and delivery, leading to more effective targeted as well as safer treatments for patients. ​Oncimmune's immunodiagnostic technology, EarlyCDT, can detect and help identify cancer on average four years earlier than standard clinical diagnosis. Our lead diagnostic test, EarlyCDT Lung, targets a vast market estimated to grow to £3.8bn by 2024. With over 200,000 tests already performed for patients worldwide and its use being supported by peer reviewed data in over 12,000 patients, we are poised to become an integral component of future lung cancer detection programmes, globally.


Oncimmune, headquartered at its laboratory facility in Nottingham, UK, has a discovery research centre in Dortmund, Germany and a partner representative office in Shanghai, China.


Further information is available at www.oncimmune.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.